<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388322</url>
  </required_header>
  <id_info>
    <org_study_id>HOPPE‐Trial</org_study_id>
    <secondary_id>2010‐023597‐39</secondary_id>
    <nct_id>NCT01388322</nct_id>
  </id_info>
  <brief_title>Low Weight Heparin prOphylaxis for Placental‐Mediated Complications of PrEgnancy</brief_title>
  <acronym>HOPPE</acronym>
  <official_title>Enoxaparin for the Prevention of Placental‐Mediated Complications of Pregnancy in Women With Obstetric History or Abnormal Uterine Artery Doppler at First Trimester Ultrasound and Without Thrombophilia: a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Cruces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parc Sanitari Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multicenter, randomized, open‐label, parallel groups study to test the hypothesis
      that prophylactic low molecular weight heparin (LMWH) (enoxaparin) initiated before 14 weeks
      of gestation could improve maternal and perinatal outcome in women at high risk for
      developing placental‐mediated pregnancy complications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of any of these complications of placental insufficiency</measure>
    <time_frame>from date of randomization until the date of delivery (assessed up to 30 weeks)</time_frame>
    <description>Development of any of these complications of placental insufficiency: preeclampsia, intrauterine growth restriction, abruption placentae, and/or intrauterine fetal demise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at birth</measure>
    <time_frame>from date of randomization until the date of delivery (assessed up to 30 weeks)</time_frame>
    <description>Gestational age at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization during pregnancy</measure>
    <time_frame>from randomization to the time of delivery (30 weeks)</time_frame>
    <description>Days of hospitalization during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of maternal hospitalization in the postpartum period</measure>
    <time_frame>from delivery until discharge (an expected average of one week)</time_frame>
    <description>Days of maternal hospitalization in the postpartum period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Data</measure>
    <time_frame>after the delivery (an expected average of one month)</time_frame>
    <description>weight, height, head circumference, Apgar score 1‐5 min, arterial pH, venous base excess (BE) of umbilical cord gases, and complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">361</enrollment>
  <condition>High Risk Pregnant Women</condition>
  <condition>Placental Insufficiency</condition>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration of one dose daily of enoxaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>expectant management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual management</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>40 mg (4000 IU) women &lt;80 kg at the time of randomization or 60 mg (6000 IU) women&gt; 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.</description>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women ≥18 years

          -  Gestational age &lt; 14 weeks at randomisation

          -  One or more of the following complications in a previous pregnancy:

               -  Severe PE resulting in delivery before 32 weeks of gestation

               -  Newborn weight less than the 10th percentile and documented abnormal Doppler in
                  the umbilical artery during pregnancy before 32 weeks gestation

               -  Abruption of placenta

               -  Unexplained intrauterine death between 20‐41,6 weeks of gestation secondary of
                  placental insufficiency or

          -  Uterine arteries Pulsatility Index (mPI) Doppler ≥95th percentile at 11‐14 weeks of
             gestation.

        Exclusion Criteria:

          -  Multiple pregnancy

          -  Abnormal thrombophilia study

          -  Alcohol or illicit drug use

          -  Severe fetal malformations or chromosomal abnormalities

          -  Previous history of infertility ( 3 or more early miscarriages)

          -  Maternal HIV, Cytomegalovirus or toxoplasma infection

          -  Known fetal abnormality or chromosomal defect at randomisation

          -  Women with previous venous or arterial thrombotic event

          -  Organic lesions that could increase the hemorrhagic risk: gastric ulcus, stroke, a
             recent hemorrhagic event, high risk situations for hemorrhagic event

          -  Known allergy to heparin or LMWH, thrombopenia or thrombosis episode due to heparin
             treatment

          -  Contraindication to LMWH

          -  An absolute indication for anticoagulant therapy: venous deep thrombosis, pulmonary
             embolism, ovaric hyperestimulation, cardiophaty, others

          -  Metabolic disorders a risk for development of PE and/or IUGR: Type I diabetes,
             hipertiroidism, chronic renal insufficiency
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lluís Cabero, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisa Llurba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Dolores Gómez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Joan de Deu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Txantón Martínez-Astorquiza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Cruces</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul De Diego, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parc Sanitari Sant Joan de Deu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc sanitari Sant Joan de Deu</name>
      <address>
        <city>Sant Boi de Llobregat</city>
        <state>Barcelona</state>
        <zip>08830</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Placental insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Placental Insufficiency</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

